Decibel Therapeutics, Inc. Common Stock
DBTX
DBTX was delisted on the 22nd of September, 2023.
42 hedge funds and large institutions have $75.2M invested in Decibel Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 7 closing their positions.
314% more call options, than puts
Call options by funds: $1.41M | Put options by funds: $340K
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
40% more capital invested
Capital invested by funds: $53.8M → $75.2M (+$21.4M)
8% more funds holding
Funds holding: 39 → 42 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$732K |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$602K |
| 3 |
Millennium Management
New York
|
+$533K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$532K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$207K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$1M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$836K |
| 3 |
SCM
Suvretta Capital Management
New York
|
-$801K |
| 4 |
Two Sigma Investments
New York
|
-$68K |
| 5 |
B
Bailard
Foster City,
California
|
-$60K |
DBTX Hedge Fund Activity: Q2 2022 in Review
42 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Decibel Therapeutics, Inc. Common Stock (DBTX) for Q2 2022, worth a combined $75.2M — up 40% from $53.8M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new DBTX positions and 7 closed out — a net gain of 3 holders — while 9 added to existing stakes and 11 trimmed.
The largest buyer was Newtyn Management, opening a new position worth an estimated $732K. The largest seller was Casdin Capital, exiting entirely with an estimated $1M sold.
- 42 institutional investors held Decibel Therapeutics, Inc. Common Stock (DBTX) as of Q2 2022, up from 39 in Q1 2022.
- Funds reported $75.2M of Decibel Therapeutics, Inc. Common Stock stock for Q2 2022, up 40% quarter-over-quarter.
- 10 funds opened new Decibel Therapeutics, Inc. Common Stock positions in Q2 2022 and 7 closed out, a net change of +3 holders.
- The largest Decibel Therapeutics, Inc. Common Stock buyer in Q2 2022 was Newtyn Management, an estimated $732K added.
- The largest Decibel Therapeutics, Inc. Common Stock seller in Q2 2022 was Casdin Capital, an estimated $1M sold.
Based on aggregated 13F filings for Q2 2022.